Reader Response: AAN Position Statement: Ethical Issues in Clinical Research in Neurology
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In their update to the AAN's statement on research ethics, Tolchin et al.1 provided a thoughtful consideration of how to do clinical research but say little about when or why to conduct a randomized clinical trial (RCT). The 7-step criteria put forward by Emanuel et al.2—and on which the statement is based—speaks to this issue indirectly, but we suggest going even further. The AAN statement provides a valuable opportunity to mandate that the ethical justification for neurologic RCTs be explicit and codified. Specifically, we have proposed that RCTs be conducted only if there is uncertainty surrounding a clear hypothesis as explicitly demonstrated through a systematic review.3 Moreover, we have shown this standard is rarely met.4 We believe this issue is of pressing importance, especially in the era of COVID-19. For example, medicine has been challenged by unfounded claims about the efficacy of hydroxychloroquine for COVID-19,5 which has provoked calls for RCTs. Researchers have responded: a search of clinicialtrials.gov reveals 133 active or upcoming trials. Are all these trials necessary? Are any? Hydroxychloroquine has significant risks. Without transparent and codified standards for determining when RCTs should be performed, patients will suffer from being recruited into useless, redundant, or harmful trials.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.